The Manufacturers Life Insurance Company Buys 5,291 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

The Manufacturers Life Insurance Company raised its position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 10.1% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 57,805 shares of the company’s stock after acquiring an additional 5,291 shares during the period. The Manufacturers Life Insurance Company’s holdings in Xeris Biopharma were worth $130,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. AQR Capital Management LLC boosted its stake in shares of Xeris Biopharma by 4.6% during the 2nd quarter. AQR Capital Management LLC now owns 1,193,080 shares of the company’s stock worth $2,684,000 after purchasing an additional 52,074 shares during the period. Asset Management Group Inc. boosted its position in shares of Xeris Biopharma by 130.7% during the second quarter. Asset Management Group Inc. now owns 26,480 shares of the company’s stock valued at $60,000 after buying an additional 15,000 shares during the period. Renaissance Technologies LLC grew its stake in shares of Xeris Biopharma by 33.9% during the second quarter. Renaissance Technologies LLC now owns 1,351,640 shares of the company’s stock valued at $3,041,000 after buying an additional 342,300 shares during the last quarter. Rhumbline Advisers raised its holdings in shares of Xeris Biopharma by 6.9% in the second quarter. Rhumbline Advisers now owns 189,970 shares of the company’s stock worth $427,000 after buying an additional 12,332 shares during the period. Finally, Allspring Global Investments Holdings LLC raised its holdings in shares of Xeris Biopharma by 4,512.5% in the second quarter. Allspring Global Investments Holdings LLC now owns 16,282 shares of the company’s stock worth $37,000 after buying an additional 15,929 shares during the period. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Xeris Biopharma in a research report on Thursday, August 15th.

Xeris Biopharma Price Performance

Xeris Biopharma stock opened at $3.06 on Friday. The stock has a market cap of $453.66 million, a price-to-earnings ratio of -6.51 and a beta of 2.76. The firm has a 50-day moving average of $2.81 and a two-hundred day moving average of $2.36. Xeris Biopharma Holdings, Inc. has a 1 year low of $1.46 and a 1 year high of $3.26.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01. The firm had revenue of $48.07 million during the quarter, compared to analyst estimates of $46.80 million. Xeris Biopharma had a negative return on equity of 16,662.63% and a negative net margin of 32.83%. During the same quarter in the previous year, the business earned ($0.14) earnings per share. Research analysts expect that Xeris Biopharma Holdings, Inc. will post -0.4 earnings per share for the current year.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.